Stock Movers: NatWest, Sanofi, and Saab Report Strong Earnings

NatWest's Financial Performance

• 🏦 NatWest reported its highest earnings in at least a decade, raising its income and returns guidance for the year.
• 📈 The bank's net interest margin, a key profitability measure, was higher than expected.
• ✅ NatWest set aside less than anticipated for bad loans, indicating a strong loan portfolio quality.
• 🌟 NatWest's results were considered the most impressive among UK banks reporting this week, leading to a significant share price increase.

Sanofi's Pharmaceutical Success

• 💊 Sanofi's profit exceeded analyst expectations due to robust demand for its blockbuster drug, Dupixent, used for skin and asthma conditions.
• 🚀 Dupixent sales reached a record high, projected to generate over 21 billion euros annually at its peak, making it Sanofi's largest medicine.
• 📉 Conversely, Sanofi experienced a significant drop in flu shot sales, attributed to price competition in Europe and lower vaccination rates in the US.
• 💬 Sanofi is in ongoing discussions with the US regarding tariffs, though no deal has been reached to lower drug costs in exchange for tariff relief.

Saab's Defense Sector Growth

• 🛡️ Swedish defense company Saab increased its full-year organic revenue forecast, benefiting from the current geopolitical landscape.
• 💼 Saab reported a record high order backlog, signaling strong demand for its products.
• 🚀 The CEO anticipates sustained momentum for the company, supported by increased global military spending.
• 🇩🇪 German defense firm Hensoldt also reported positive results, with margin guidance exceeding estimates and a subsequent stock price rise.